It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

Yun Ki-wook, a professor in SNUH's Department of Pediatric Infectious Diseases, discusses the domestic release of Beyfortus, an antibody treatment for respiratory syncytial virus, during a press ...

Sanofi’s plan to become a dominant player in the respiratory syncytial virus (RSV) market has moved a step closer, with FDA approval of Beyfortus for the prevention of RSV disease in infants.

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

SNY’s RSV vaccine, called Beyfortus, was a key driver for its previous quarter, and its Q4 could be a repeat since it’s typically seasonally strong for vaccines. The company also has a robust ...

The beyfortus market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX ...

Immunology saw significant contributions from Beyfortus royalties, although Synagis declined year-over-year. Pipeline progress included the U.S. filing for Gamifant in secondary HLH and the ...

Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with Beyfortus becoming a blockbuster in its first full year of sales. We exceeded our business EPS ...

Sanofi could be "bit more" active with M&A in near future, CFO says Sanofi's R&D spending to see limited increase in 2025 Beyfortus sales double, Dupixent sales miss estimates Jan 30 - Sanofi ...

Chief Executive Officer Paul Hudson is focused on boosting Sanofi’s drug development, hoping to produce more blockbusters like Beyfortus, which protects against the respiratory syncytial virus.

Beyfortus reached blockbuster status in its first full year of sales, contributing significantly to the company's growth. The company's vaccines business crossed the EUR8 billion milestone ...